Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment
Sponsor: Advenchen Pharmaceuticals, LLC.
Summary
This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .
Official title: A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2022-11-01
Completion Date
2028-12
Last Updated
2026-05-08
Healthy Volunteers
No
Interventions
AL8326 40 mg
Taken AL3826 at 40mg QD orally
AL8326 60 mg
Taken AL3826 at 60mg QD orally
AL8326 80 mg--stopped
Taken AL3826 at 80 mg QD orally
Locations (7)
University of Alabama at Birmingham
Birmingham, Alabama, United States
Cleveland Clinic Florida
Weston, Florida, United States
Northwestern University
Chicago, Illinois, United States
Siteman Cancer Center, Washington University
St Louis, Missouri, United States
Cleveland Clinic
Cleveland, Ohio, United States
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Ramón Y Cajal
Madrid, Spain